Introduction
CMD, T2D, cardiometabolic disease, Cancer
CVD, EVENTS, TYPE 2 DIABETES, CANCER
Reducing dietary SFAs has been proposed as a modifiable dietary strategy to help prevent cardiometabolic disease (CMD) risk worldwide [Plasma lipids mostly derive from nutrient intakes, along with lipids stored and/or endogenously synthesized in the liver and adipose tissue [Methodological constraints have been important obstacles to the assessment of the causal relationship between dietary intakes, CMD risk markers, and CMD events. To date, established knowledge on the role of dietary fat on CMD risk derives from interventional studies such as randomized controlled trials (RCTs), which usually investigate the direct effect of dietary fat on short- to medium-term changes in CMD risk markers, to observational prospective cohort studies, which allow for the long-term follow-up necessary to observe CMD events in large populations. Therefore, there is a need for intersectional research that would provide novel insights into CMD etiology. To that end, recent analysis of the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study investigated lipidome-wide CMD association analyses across different lipidomics levels and identified direct associations between SFA-containing glycerolipids in plasma and CVD or type 2 diabetes (T2D) incidence, along with direct associations between ceramides and CVD risk [